Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease.

Blood - 24 Nov 2011

Fowler Jessica A, Lwin Seint T, Drake Matthew T, Edwards James R, Kyle Robert A, Mundy Gregory R, Edwards Claire M

Abstract excerpt

The contributions of the host microenvironment to the pathogenesis of multiple myeloma, including progression from the non-malignant disorder monoclonal gammopathy of undetermined significance, are poorly understood. In the present study, microarray analysis of a murine model requiring a unique host microenvironment for myeloma development identified decreased host-derived adiponectin compared with normal mice....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adiponectin
Share to Bone Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Neoplasms

Share to Molecular Targeted Therapy

Share to Multiple Myeloma

Share to Neoplasm Transplantation

Share to Tumor Microenvironment

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 21908434
DOI: 10.1182/blood-2011-01-330407
PMCID: PMC3228502

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease.PMID 21908434Read ↗

Myeloma-Modified Adipocytes Exhibit Metabolic Dysfunction and a Senescence-Associated Secretory Phenotype.Semantic proximity Read ↗

Ablation of CD38 in multiple myeloma cells leads to an aggressive phenotype in a mouse xenograft model.Semantic proximity Read ↗

The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma PathogenesisSemantic proximity Read ↗

Immune-mediated tumor control in the 5TGM1 transfer model of multiple myelomaSemantic proximity Read ↗

LAGλ-1: A clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myelomaSemantic proximity Read ↗

CD45neg but Not CD45pos Human Myeloma Cells Are Sensitive to the Inhibition of IGF-1 Signaling by a Murine Anti-IGF-1R Monoclonal Antibody, mAVE1642Semantic proximity Read ↗

Association of lipid levels, adipokines and multiple myeloma: a two-sample multivariate Mendelian randomization study.Semantic proximity Read ↗

Target therapy of multiple myeloma by PTX-NPs and ABCG2 antibody in a mouse xenograft model.Semantic proximity Read ↗

Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients.Semantic proximity Read ↗

Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: <i>In Vitro</i> and <i>In Vivo</i> EvidenceSemantic proximity Read ↗

Bone morphogenetic protein 4 gene therapy in mice inhibits myeloma tumor growth, but has a negative impact on boneSemantic proximity Read ↗

TPL2 kinase regulates the inflammatory milieu of the myeloma nicheSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.